In this phase 3 study of nivolumab (or nivolumab plus ipilimumab) versus ipilimumab alone in previously untreated advanced melanoma, immunotherapy led to an overall survival (OS) benefit in patients with a lower tumor PD-L1 expression level. This evidence concerns the gene CD274 and neoplasm.